Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prefuvir mesylate
- Development stage
- Unknown
- Lead developer
- Hefei Life Science Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Prefuvir mesylate is a small molecule nucleotide reverse transcriptase inhibitor (NRTI) and a prodrug of tenofovir, developed by Hefei Life Science Research Institute for the treatment of chronic hepatitis B virus (HBV) infection. It is designed to be more stable in plasma than tenofovir disoproxil fumarate (TDF), allowing for more efficient delivery of the active metabolite, tenofovir diphosphate, to hepatocytes. This targeted delivery aims to achieve potent antiviral efficacy at lower doses, thereby minimizing systemic exposure to tenofovir and reducing the risk of renal impairment and bone mineral density loss. It is currently being evaluated in Phase 3 clinical trials and real-world observational studies in China.
- Other names
- prefuvirPufuwe甲磺酸普福韦
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on prefuvir mesylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prefuvir mesylate.